Pinnacle West Capital Corporation Stock 12‑Month Price Target Cut to $106.75, Implies 7% Upside
Analyst estimates for Pinnacle West Capital Corp. show its average 12-month price target cut to $106.75 from $107.62. The range is $97 to $129 per share, implying about 7% upside versus the Aug. 11 close. The consensus rating remains “Hold” with 3 Buys, 13 Holds, and 2 Sells, per 18 analysts.
How this was made
The 30-second read
Why it matters
For PNW, the actionable signal is the direction and magnitude of the consensus target change, not a new operational or financial disclosure.
Market read
Consensus target is slightly lower, implying about 7% upside versus the Aug. 11 close, but the rating mix remains predominantly Hold.
What to watch
The article does not provide the underlying thesis for the target cut, so traders may be over-weighting the target change versus any unreported company-specific developments.
Background
The piece summarizes FactSet-sourced analyst consensus: average 12-month price target, its range, and the distribution of Buy/Hold/Sell ratings.
Ticker impact
Analysts cut Pinnacle West Capital’s 12-month average price target from $107.62 to $106.75, with a Hold consensus rating unchanged.
Likely limited near-term impact; any reaction should be small unless traders treat the target cut as a proxy for deteriorating expectations.
The only disclosed change is the consensus target level, while the consensus rating remains Hold (3 Buys, 13 Holds, 2 Sells). No earnings, guidance, or company-specific event is reported.
Market effects
Minimal, since this is a single-name analyst target adjustment with no sector-wide regulatory or demand shock described.
Minimal, no regional policy or utility-specific event is cited.
Low, the update is analyst consensus data without cross-border catalysts.
Counterpoint
A small target reduction may reflect analyst model updates rather than a fundamental deterioration, especially with the consensus rating staying at Hold.
Key entities
- equityPinnacle West Capital Corporation
Subject of the article, with a consensus 12-month price target cut to $106.75 and Hold rating maintained.
